



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

5 March 2025
EMA/63235/2025
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 24-27 February 2025

During its February 2025 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME: 1 was granted and 1 was denied. The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Eligibility granted

Name*	Product type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
NGN-401	Advanced Therapy Medicinal Product	Congenital, familial and genetic disorders	Treatment of Rett syndrome	Non-clinical + clinical exploratory	SME

* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.




Eligibility denied

Product type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Advanced Therapy Medicinal Product	Congenital, familial and genetic disorders	Treatment of Friedreich's ataxia	Non-clinical + clinical exploratory	SME

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of PRIME eligibility recommendations adopted by 27 February 2025

■ Granted
 ■ Denied
 ■ Out of scope*
 ■ Withdrawn



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.